Incidence and outcome of acute renal failure complicating autologous stem cell
transplantation for AL amyloidosis. Background High-dose intravenous melphalan and …

High-dose intravenous melphalan with autologous stem cell transplantation in AL
amyloidosis-associated end-stage renal disease. Background The development of end …

Therapies for AL amyloidosis have dramatically improved, leading to longer patient survival;
however, more AL amyloidosis patients are reaching end-stage renal disease (ESRD) …

Effective systemic therapies suppress toxic light chain production leading to an increased
proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end …

Background: Primary systemic (AL) amyloidosis is a rare plasma cell disorder characterized
by soft-tissue deposition of monoclonal light chain fragments. High-dose melphalan followed …

Background Although the use of bortezomib alone and in combination with steroids has
shown efficacy in AL amyloidosis, its role in combination with high-dose melphalan and …

Background: Dose-intensive intravenous melphalan with autologous blood stem-cell
transplantation induces remission of the plasma cell dyscrasia in a substantial proportion of …

Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose
melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen …

High‐dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for
selected patients with AL amyloidosis. We report the long‐term outcomes of 648 patients …

Background: Patients with primary systemic amyloidosis (AL) have a poor prognosis.
Median survival time from standard treatments is only 17 months. High-dose intravenous …